Breast Density, Elevated Breast Cancer Risk Highest in Hispanic Women

TON - March 2017, Vol 10, No 2 - Breast Cancer
Meg Barbor, MPH

Cape Town, South Africa—Breast density, which can affect the visualization of mammography, is one of the strongest and most consistent risk factors for breast cancer. Women with the highest mammographic density (≥75%) are at a 4- to 6-fold increased risk for developing breast cancer compared with women with the least dense tissue.

Although an estimated 50% of women in the United States have dense breasts, data on ethnic variations in breast density and breast cancer risk are limited. Research on this topic has seldom included minorities, such as black and Hispanic women, according to a group of researchers at Georgetown University in Washington, DC.

The team, led by Bridget Oppong, MD, Assistant Professor of Surgery, Division of Breast Surgery, Georgetown University Hospital of Surgery, Washington, DC, conducted an investigation into the differences in breast cancer risk among varying ethnic populations and presented the results in a poster at the American Association for Cancer Research International Conference on New Frontiers in Cancer Research.

The researchers reviewed breast density recorded at initial mammographic screening in women who presented to the Capital Breast Care Center and Georgetown University Hospital from 2010 to 2014. From imaging reports, they recorded the American College of Radiology BI-RADS density categories; 1, fatty; 2, scattered fibroglandular densities; 3, heterogeneously dense; and 4, extremely dense.

From 2010 to 2014, mammographic density was recorded for 2147 women: 940 (43.8%) black, 893 (41.6%) Hispanic, and 314 (14.6%) white. The investigators observed high breast density (categories 3 and 4) in Hispanic, premenopausal, nonobese women without children (P <.001), and found that these characteristics were predictive of high mammographic density. Obese women were 70% less likely to have high breast density than nonobese women.

In this analysis, Hispanic women were found to have the highest breast density, followed by black women, with white women having the lowest. The breast density and cancer interplay may be a crucial element in addressing racial and ethnic disparities in breast cancer outcomes, but further investigation of the impact of obesity on breast density in the understudied Hispanic population is needed.

“As there is a paucity of reporting on mammographic density in minority women, these data presented are valuable, especially as we are able to have a comparison group of whites,” the researchers noted.

Related Items
Explaining Treatment Regimens to Patients with HR+/HER2- Metastatic Breast Cancer
Thomas Bachelot, MD, PhD
Video Library published on July 19, 2018 in Breast Cancer, Video
HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms
Hope S. Rugo, MD
Video Library published on July 19, 2018 in Breast Cancer, Video
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Updates on Immunotherapy in Advanced Melanoma
Meg Barbor, MPH
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Melanoma, HOPA 2018 Highlights
Understanding Immunotherapy Late Adverse Effects in Cancer Survivors
Meg Barbor, MPH
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Adverse Effects
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Adverse Effects, Breast Cancer
Targeting FMS-Like Tyrosine Kinase 3 in the Management of Patients with FLT3-Positive Acute Myeloid Leukemia
Meg Barbor, MPH
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in HOPA 2018 Highlights, Leukemia
The Strengths and Pitfalls of PD-L1 as a Biomarker for Immunotherapy
Meg Barbor, MPH
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in HOPA 2018 Highlights
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TOP Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only
Last modified: March 7, 2017